In a retrospective study of 352 patients with primary myelodysplastic syndromes, 61 (17.3%) revealed myelofibrosis in bone marrow biopsies. The fibrosis was observed to occur mostly focally (41/61 cases), and collagen deposits were found very rarely (4/61). The histopathology of bone marrow biopsies revealed hyperplasia and disturbed differentiation in megakaryopoiesis; the frequency and grade of dysplasia in megakaryopoiesis increased with advancing myelofibrosis. Reticulin fibrosis occurred in all subtypes of MDS; however, there was a higher incidence in chronic myelo-monocytic leukaemia (CMMoL). The frequency of cytogenetic aberrations was significantly higher in the MDS cases with myelofibrosis, compared to the cases without fibrosis. Clinical data showed significantly lower values of haemoglobin and lower platelet counts in MDS with myelofibrosis. Life expectancy was reduced to 9.6 months, compared with 17.4 months in MDS without fibrosis. In refractory anaemia, the survival times were 10.0 months in MDS with myelofibrosis, compared to 28.9 months in MDS without myelofibrosis. 36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease. Myelofibrosis therefore seems to herald a poor prognosis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety.
Cancer
January 2025
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib was approved by the US Food and Drug Administration in 2014 for treatment of patients with polycythemia vera (PV) who have an inadequate response to or intolerance of hydroxyurea (HU). PV is a chronic myeloproliferative neoplasm defined by primary absolute erythrocytosis, bone marrow hypercellularity, and JAK mutations such as JAK2V617F. Patients with PV experience burdensome symptoms and are at risk of thromboembolic events, in particular those with resistance to or intolerance of initial treatments such as HU.
View Article and Find Full Text PDFArticle Synopsis
- Splenomegaly is a common issue in patients with chronic blood cancers, and while splenectomy is effective, it poses significant risks; this study examines the use of magnetic resonance guided radiation therapy (MRgRT) as a treatment option.
- The study involved a retrospective analysis of 12 patients with myelofibrosis and myelodysplastic/myeloproliferative neoplasms who received targeted radiation to their spleens, resulting in pain relief and substantial reductions in spleen size.
- Findings suggest that MRgRT for splenic irradiation can be effective with minimal non-hematological side effects, but further research is necessary to confirm long-term efficacy and safety in larger populations.
Article Synopsis
- Some JAK inhibitors like ruxolitinib can worsen anemia in myelofibrosis patients; switching to momelotinib may be more beneficial for managing anemia while maintaining symptom control.
- The SIMPLIFY-2 trial compared momelotinib with best available therapy (mostly ruxolitinib) in JAK inhibitor-experienced patients, revealing better transfusion independence rates in those switched to momelotinib.
- Patients with lower baseline hemoglobin levels experienced greater improvements in mean hemoglobin and overall outcomes with momelotinib, suggesting it's a better option for those struggling with anemia.
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.
Br J Haematol
July 2024
Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Article Synopsis
- * Recent findings show that adolescents and young adults (15-39 years) can make up to 20% of MPN cases, presenting unique mutations and increased risks of severe complications compared to older patients.
- * There is a pressing need for effective and tolerable treatment options for young patients with MPN, as many will live with the condition for a long time; this review discusses their specific
Neuropilin2 in Mesenchymal Stromal Cells as a Potential Novel Therapeutic Target in Myelofibrosis.
Cancers (Basel)
May 2024
Institute for Pathology, University Hospital Bonn, 53127 Bonn, Germany.
Bone marrow fibrosis in myeloproliferative neoplasm (MPN), myelodysplastic syndromes (MDS), MPN/MDS overlap syndromes and acute myeloid leukemia (AML) is associated with poor prognosis and early treatment failure. Myelofibrosis (MF) is accompanied by reprogramming of multipotent bone marrow mesenchymal stromal cells (MSC) into osteoid and fiber-producing stromal cells. We demonstrate NRP2 and osteolineage marker NCAM1 (neural cell adhesion molecule 1) expression within the endosteal niche in normal bone marrow and aberrantly in MPN, MDS MPN/MDS overlap syndromes and AML ( = 99), as assessed by immunohistochemistry.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!